Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake with $190K Share Purchases
Insider Trading Report
Cryo-Cell International's Chairman and Co-CEO, David Portnoy, significantly increased his beneficial ownership through multiple common stock purchases totaling over $190,000.
Summary
- David Portnoy, Chairman, Co-CEO, Director, and 10% Owner of Cryo-Cell International Inc. (CCEL), acquired a total of 42,800 shares of common stock between September 8 and September 10, 2025, for a total value of approximately $190,065.
- The purchases were executed at weighted average prices ranging from $4.31 to $4.49 per share.
- These acquisitions were made through various accounts, including his IRA, as custodian for his son, directly, and indirectly through entities like PartnerCommunity, Inc., uTIPu, Inc., and by his spouse.
- Following these transactions, Portnoy's beneficial ownership includes 811,920 shares held directly, 268,878 shares via IRA, 107,403 shares by his spouse, 10,939 shares as custodian for his son, 160,082 shares by PartnerCommunity, Inc., 57,306 shares by uTIPu, Inc., 164,182 shares by 401K, and 59,027 shares by Mayim Limited Partnership.
- Portnoy also holds various stock options with exercise prices from $4.30 to $12.27, with vesting schedules extending to 2027 and 2028, and one performance-based option vesting if the stock reaches $25.00 per share.
Sentiment
Score: 8
Explanation: The significant insider buying by a top executive and major shareholder indicates strong confidence in the company's future prospects and current valuation, which is a very positive signal for investors.
Positives
- Significant insider buying by a key executive (Chairman, Co-CEO, Director, and 10% Owner) signals strong confidence in the company's future prospects.
- The purchases were made at market prices, indicating a belief that the current stock valuation offers an attractive entry point.
- The diversified nature of the purchases (direct, IRA, custodian, corporate entities, spouse) demonstrates a broad commitment to increasing personal and affiliated holdings.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance, beyond the vesting schedules of stock options. The significant insider buying itself can be interpreted as a positive outlook from management regarding the company's future performance.
Management Comments
- The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Industry Context
Insider buying in the biotechnology or stem cell banking sector can signal management's confidence in upcoming clinical trial results, regulatory approvals, or market expansion, especially given the long-term nature of some of the derivative holdings. This particular filing, however, does not provide specific industry context beyond the company's name.
Comparison to Industry Standards
- Insider buying is a common occurrence across all industries. The magnitude of this purchase, over $190,000, by a top executive and significant owner, is substantial and generally viewed favorably by investors as it aligns management's interests with shareholders.
- Without specific comparable transactions from other companies in the stem cell banking industry, a direct comparison is difficult, but the action itself is a strong positive signal.
Related Party Transactions
- The filing details indirect beneficial ownership through entities where David Portnoy has control or influence, such as PartnerCommunity, Inc., uTIPu, Inc., and Mayim Limited Partnership, as well as purchases made by his spouse and as custodian for his son. These are standard disclosures for related party beneficial ownership in a Form 4.
Stakeholder Impact
- Shareholders: Likely positive, as significant insider buying often boosts investor confidence and may lead to increased share price. It signals management's belief in the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Date stock option with $7.53 exercise price became exercisable. |
| 12/20/2019 | Date stock option with $7.28 exercise price became exercisable. |
| 12/22/2021 | Date stock option with $12.27 exercise price was granted, with immediate vesting if stock reaches $25.00. |
| 12/23/2022 | Date stock option with $4.30 exercise price became exercisable. |
| 01/03/2023 | Date stock option with $4.77 exercise price was granted, with partial vesting upon issuance. |
| 12/22/2023 | Date stock option with $6.47 exercise price was granted, with partial vesting upon issuance. |
| 01/02/2024 | Vesting date for 8,749 stock options with $4.77 exercise price. |
| 12/22/2024 | Vesting date for 1/3 of stock options with $6.47 exercise price. |
| 01/21/2025 | Date stock option with $8.08 exercise price was granted, with partial vesting upon issuance. |
| 09/08/2025 | Date of earliest common stock transaction by David Portnoy. |
| 09/09/2025 | Date of common stock transactions by David Portnoy. |
| 09/10/2025 | Date of common stock transactions by David Portnoy and filing signature date. |
| 01/02/2025 | Vesting date for 21,000 stock options with $4.77 exercise price. |
| 12/22/2025 | Vesting date for 1/3 of stock options with $6.47 exercise price. |
| 01/02/2026 | Vesting date for 11,501 stock options with $4.77 exercise price. |
| 01/21/2026 | Vesting date for 1/3 of stock options with $8.08 exercise price. |
| 01/21/2027 | Vesting date for 1/3 of stock options with $8.08 exercise price. |
| 12/23/2027 | Expiration date for stock option with $4.30 exercise price. |
| 01/03/2028 | Expiration date for stock option with $4.77 exercise price. |
| 12/22/2028 | Expiration date for stock options with $12.27 and $6.47 exercise prices. |
| 08/30/2029 | Expiration date for stock option with $7.53 exercise price. |
| 12/20/2029 | Expiration date for stock option with $7.28 exercise price. |
| 01/21/2030 | Expiration date for stock option with $8.08 exercise price. |
Recommendation
strong buyThe substantial insider buying by David Portnoy, who holds multiple key executive and board positions and is a 10% owner, is a very strong bullish signal. Executives typically have the most intimate knowledge of a company's operations and future prospects. Their willingness to invest personal capital at current market prices suggests a belief that the stock is undervalued and poised for future appreciation. This action aligns management's interests directly with shareholders and provides a compelling reason for investors to consider a 'strong buy' position.
Keywords
Cryo-Cell International, CCEL, David Portnoy, Insider Buying, Form 4, Stock Purchase, Beneficial Ownership, Executive Stock Acquisition, Biotechnology, Stem Cell Banking
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.